From the Guidelines
Morphine should be avoided in patients with renal insufficiency (GFR <30 mL/min/1.73 m2) and ESRD due to the risk of accumulation of its active metabolites and increased toxicity. According to the most recent and highest quality study 1, opioids primarily eliminated in urine, such as morphine, should be avoided in patients with renal impairment, unless there are no alternatives. The study recommends rotating to methadone, if not contraindicated, as this agent is excreted fecally.
Some key points to consider when managing patients with renal impairment and opioid use include:
- Avoiding morphine, meperidine, codeine, and tramadol in patients with renal impairment 1
- Carefully titrating and frequently monitoring opioids primarily eliminated in urine, such as fentanyl, oxycodone, and hydromorphone 1
- Performing more frequent clinical observation and opioid dose adjustment in patients with renal or hepatic impairment 1
- Considering alternative opioids with fewer active metabolites, such as fentanyl or hydromorphone, for patients with end-stage renal disease requiring ongoing pain management 2, 1
It is essential to monitor patients closely for signs of toxicity, such as excessive drowsiness, confusion, respiratory depression, and myoclonus, and to adjust opioid doses based on clinical response rather than standard dosing protocols. Regular reassessment of pain control and side effects is crucial to ensure optimal management of patients with renal impairment and opioid use.
From the Research
Morphine Renal Toxicity
- Morphine can accumulate in patients with renal impairment, leading to toxicity 3, 4, 5
- The active metabolite of morphine, morphine-6-glucuronide, is usually renally excreted and can accumulate in patients with renal failure, causing severe and prolonged respiratory depression 5
- Patients with creatinine clearance below 30 ml/min should avoid morphine due to the risk of accumulation and toxicity 3
- Alternative opioids such as fentanyl, alfentanil, and buprenorphine can be used safely in patients with renal impairment 3
- Hydromorphone, another opioid, can also accumulate in patients with renal insufficiency, leading to neuroexcitatory phenomena such as tremor, myoclonus, agitation, and cognitive dysfunction 6
- The use of morphine or hydromorphone in patients with renal impairment may be associated with neurotoxic effects, but the current evidence is of very low quality and conflicting 7
Key Findings
- Morphine and its metabolites can accumulate in patients with renal impairment, leading to toxicity 3, 4, 5
- Alternative opioids should be considered in patients with renal impairment 3
- Close monitoring for neurotoxic effects is necessary when using morphine or hydromorphone in patients with renal impairment, particularly when used in high doses and for extended duration 7